Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Abstract Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists rega...

Bibliografske podrobnosti
Main Authors:	Raj Parikh, Ippokratis Konstantinidis, David M. O'Sullivan, Harrison W. Farber
Format:	Article
Jezik:	English
Izdano:	Wiley 2022-10-01
Serija:	Pulmonary Circulation
Teme:	idiopathic pulmonary fibrosis interstitial lung disease prostacyclin pulmonary hypertension treprostinil
Online dostop:	https://doi.org/10.1002/pul2.12141

Podobne knjige/članki

The PH‐ILD Detection tool: External validation and use in patients with ILD
od: Raj Parikh, et al.
Izdano: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
od: Julia McSweeney, et al.
Izdano: (2023-04-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
od: Aparna C. Swaminathan, et al.
Izdano: (2024-11-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
od: Jenna M. Faircloth, et al.
Izdano: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
od: Jenna M. Faircloth, et al.
Izdano: (2023-08-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
od: Piotr Kędzierski, et al.
Izdano: (2025-01-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
od: Abdullah A. Alqarni, et al.
Izdano: (2023-08-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
od: Shelsey W. Johnson, et al.
Izdano: (2022-07-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
od: Nicholas S. Hill, et al.
Izdano: (2022-07-01)

Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future
od: Ahmad Arslan, et al.
Izdano: (2024-01-01)

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis
od: Ning Zhao, et al.
Izdano: (2022-11-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
od: Maria S. Nashatyreva, et al.
Izdano: (2023-01-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
od: Garance Kopp, et al.
Izdano: (2020-10-01)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
od: Kellie Morland, et al.
Izdano: (2021-10-01)

Interstitial Lung Abnormality in Asian Population
od: Gong Yong Jin
Izdano: (2024-04-01)

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
od: Mingtao Liu, et al.
Izdano: (2023-09-01)

CLINICAL PROFILE OF INTERSTITIAL LUNG DISEASES CASES
od: Gagiya Ashok K, et al.
Izdano: (2012-03-01)

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
od: Alexandra Lawrence, et al.
Izdano: (2024-09-01)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
od: Zachary A. Haynes, et al.
Izdano: (2023-10-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
od: E. A. Rezukhina, et al.
Izdano: (2021-09-01)

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy
od: N. A. Kuzubova, et al.
Izdano: (2020-11-01)

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
od: Cassady SJ, et al.
Izdano: (2024-06-01)

Osteopontin as a Biomarker in Interstitial Lung Diseases
od: David Iturbe-Fernández, et al.
Izdano: (2024-05-01)

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life
od: Sabina Anna Guler, et al.
Izdano: (2016-05-01)

Increased expiratory flows identify early interstitial lung disease
od: Sami Mohammed Alyami, et al.
Izdano: (2023-01-01)

Role of Telomere Length in Survival of Patients with Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
od: Sofía Tesolato, et al.
Izdano: (2023-12-01)

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
od: Jonathan Keow, et al.
Izdano: (2022-06-01)

Evaluation of progressive pulmonary fibrosis in non-idiopathic pulmonary fibrosis-interstitial lung diseases: a cross-sectional study
od: Özlem Erçen Diken, et al.
Izdano: (2024-08-01)

Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role
od: N A Mukhin, et al.
Izdano: (2009-03-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
od: Lianghua Xiao, et al.
Izdano: (2024-09-01)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
od: Justin M. Oldham, et al.
Izdano: (2017-08-01)

Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis
od: Pierson Richard, et al.
Izdano: (2002-02-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
od: Stephanie S. Handler, et al.
Izdano: (2022-07-01)

Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis
od: Avignat S. Patel, et al.
Izdano: (2023-02-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
od: Jia Liu, et al.
Izdano: (2024-04-01)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
od: Ji Hoon Jang, et al.
Izdano: (2024-08-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
od: Hardin EA, et al.
Izdano: (2016-11-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
od: Kazuya Ichikado, et al.
Izdano: (2023-06-01)

Noninvasive determinants of pulmonary hypertension in interstitial lung disease
od: Phillip Joseph, et al.
Izdano: (2023-01-01)

Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy
od: Aneta Kacprzak, et al.
Izdano: (2023-07-01)